Contrasting Delcath Systems (NASDAQ:DCTH) and Solventum (NYSE:SOLV)

Solventum (NYSE:SOLV) and Delcath Systems (NASDAQ:DCTH) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Profitability

This table compares Solventum and Delcath Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solventum	17.26%	25.09%	8.78%
Delcath Systems	0.56%	0.46%	0.42%

Volatility & Risk

Solventum has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.

Insider & Institutional Ownership

61.1% of Delcath Systems shares are owned by institutional investors. 0.2% of Solventum shares are owned by company insiders. Comparatively, 19.4% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Solventum and Delcath Systems, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1	3	8	0	2.58
Delcath Systems	1	0	5	1	2.86

Solventum presently has a consensus price target of $92.80, suggesting a potential upside of 3.57%. Delcath Systems has a consensus price target of $23.17, suggesting a potential upside of 48.50%. Given Delcath Systems’ stronger consensus rating and higher possible upside, analysts clearly believe Delcath Systems is more favorable than Solventum.

Valuation & Earnings

This table compares Solventum and Delcath Systems”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.32 billion	1.83	$1.56 billion	$8.18	10.95
Delcath Systems	$85.23 million	6.35	$2.70 million	$0.01	1,560.00

Solventum has higher revenue and earnings than Delcath Systems. Solventum is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Summary

Solventum beats Delcath Systems on 8 of the 15 factors compared between the two stocks.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.